[18F]-FDG-PET/CT Correlates With the Response of Radiorefractory Thyroid Cancer to Lenvatinib and Patient Survival.

Laura ValerioFederica GuidoccioCarlotta GianiElisa TardelliGiulia PucciniLuciana PuleoElisa MinaldiGiuseppe BoniRossella EliseiDuccio Volterrani

Published in: The Journal of clinical endocrinology and metabolism (2021)

Our data show that [18F]-FDG-PET/CT can early predict the response to lenvatinib and correlates with the OS of RAI-R DTC patients treated with this drug.

Keyphrases

case report
electronic health record
big data
free survival
adverse drug
data analysis
deep learning